Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
Date:11/14/2013

CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2013. 

Recent Highlights
Bremelanotide development for Female Sexual Dysfunction (FSD):

  • Successful completion of device bioequivalence trial
  • Receipt of a $1.0 million, non-refundable option fee relating to negotiation of a potential future license of bremelanotide in a defined territory outside North America
  • Pivotal Phase 3 clinical trials anticipated to start in the first quarter of calendar year 2014
  • The Company obtained patents during the quarter:

  • U.S. Patent 8,487,073, entitled "Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction" issued July 16, 2013, claiming composition of matter on novel peptides for treatment of sexual dysfunction, obesity and related indications
  • U.S. Patent No. 8,492,517, entitled "Melanocortin-1 Receptor-Specific Cyclic Peptides" issued July 23, 2013, claiming composition of matter of lead peptides for treatment of inflammation-related diseases
  • First Quarter Fiscal 2014 Financial Results
    Palatin reported a net loss of $4.5 million, or $(0.04) per basic and diluted share, for the quarter ended September 30, 2013, compared to a net loss of $10.5 million, or $(0.15) per basic and diluted share, for the same period in 2012.The decrease in net loss for the quarter ended September 30, 2013 compared to the same period last fiscal year was mainly attributable to the recognition of a $7.1 million, non-operating expense, in the quarter ended September 30, 2012, which represented the increase in fair value of warrants issued in connection with Palatin'
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
    3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
    4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
    5. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
    6. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
    7. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
    8. Palatin Technologies Announces Option for License to Bremelanotide in Europe
    9. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
    10. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
    11. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
    (Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014  The ... grow, with the publication of two papers this past ... Otolaryngology – Head and Neck Surgery , finds ... objective and subjective measures of sleep disordered breathing, leading ... the reduction in obstructive sleep apnea severity and improvement ...
    (Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners participated ... to Benefit the Radiation Oncology Institute (ROI), hosted by ... Golden Gate Park in San Francisco.  ... , CEO of Radiation Business Solutions, "but at ... raised over $70,000 for the ROI this year. This ...
    Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
    (Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... ) filings continue to grow in federal court, ... U.S. Food & Drug Administration (FDA) have voted ... treat low testosterone in men be subjected to ... risks. According to a report published on September ...
    (Date:9/20/2014)... The festival season is coming soon. The high-end ... luxurious cocktail dresses . A lot of sophisticated women ... launch a new promotion for its high quality clothes. Now, ... price, from 20 to 71 percent off. , The ... They are provided in many fashionable colors. Mary, the company’s ...
    (Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), ... new website. The new site provides the latest ... for customers. Here, people can find a lot ... Also, it has recommended some excellent web hosting ... the great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ...
    (Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
    (Date:9/20/2014)... 2014 The Arizona Advanced Manufacturing ... celebrating National Manufacturing Day by opening its doors to ... and additive manufacturing labs will be offered between 10 ... MCC’s Southern and Dobson campus (1833 W. Southern Ave, ... D. , The AzAMI at MCC was established in ...
    Breaking Medicine News(10 mins):Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
    ... of hysteria are often ticked off, by physicians, ... However, researchers from Sunnybrook Health Sciences Centre, disagree that ... emotional instability. ,Brain scans helped to detect ... in three women with hysteria. Technically, hysteria is ...
    ... U.S. hospitals spend roughly $20 billion to treat the nearly ... inpatient care//, according to a new report by HHS’ Agency ... billed for almost half of all injury cases, and more ... uninsured. The federal report also found: ,? Broken ...
    ... in Ithaca and Weill Cornell Medical College in New ... biomarkers// in cerebrospinal fluid that acts as a neurochemical ... living with Alzheimer’s disease. ,The research will ... Annals of Neurology. ,Right now, physicians rely ...
    ... India, has come up with another project. This scheme named ... to cost Rs 342.81-crores. ,The Global Fund aids ... will also be spent for reducing the transmission of HIV ... including antiretroviral therapy to those already infected. ,There ...
    ... facial is the new entrant to skin treatment in Jaipur.// ... skin or other beauty related problems, dry fruit facial is ... ,"This is a new technique and more and more ... has benefited several of my clients. It nourishes the skin ...
    ... hit upon a good device to utilize original stem cells ... of bioengineers at Carnegie Mellon University's Robotics Institute and stem ... have put together a method to organize the growth of ... Carnegie Mellon along with a team, spent time on mouse ...
    Cached Medicine News:Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 2Health News:Protein ‘Fingerprint’ in Spinal Fluid Could Spot Alzheimer’s Dise 3
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: